Placebo-associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease

Movement Disorders

Volumn 17, Issue 2, 2002, Pages 283-288

  Goetz, Christopher G ^a   Leurgans, Sue ^a,b   Raman, Rema ^b  

^a RUSH UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Parkinson's disease; Placebo; Placebo effects; Rating scales; UPDRS

Indexed keywords

PLACEBO; SELEGILINE; TOCOPHEROL;

ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; SCORING SYSTEM; UNIFIED PARKINSON DISEASE RATING SCALE;

ACTIVITIES OF DAILY LIVING; AGED; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR SKILLS; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PLACEBO EFFECT; SELEGILINE; TOCOPHEROLS;

EID: 0036523865     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10024     Document Type: Review

References (14)

1. Fahn S, Elton RL, the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, editors. Recent developments in Parkinson's disease. Vol 2. Florham Park, NJ: Macmillan Healthcare Information; 1987. p 153-163.
2. Martinez-Martin P, Gil-Nagel A, Gracia LM. Unified Parkinson's Disease Rating Scale characteristics and structure. Mov Disord 1994;9:76-83.
3. Stebbins GT, Goetz CG. Factor structure of the Unified Parkinson's Disease Rating Scale: Motor Examination section. Mov Disord 1998;13:633-636.
4. Louis ED, Lynch T, Marder K, Fahn S. Reliability of patient completion of the historical section of the UPDRS. Mov Disord 1996:11:185-192.
5. Goetz CG, Leurgans S, Raman R, Stebbins GT. Objective changes in motor function during placebo treatment in PD. Neurology 2000;54:710-714.
6. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. New Engl J Med 1993;328:176-183.
7. Marsden CD, Defects of movement in Parkinson's disease. In: Delwaide PJ, Agnoli A, editors. Restorative neurology vol 2. Amsterdam: Elsevier; 1985. p 107-115.
8. Delwaide PJ, Gonce M. Pathophysiology of Parkinson's signs. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Williams and Wilkins; 1998. p 159-175.
9. Shetty N, Friedman JH, Kieburtz K, Marshall FJ, Oakes D, and the Parkinson Study Group. The placebo response in Parkinson's disease. Mov Disord 1999;22;207-212.
10. Hubble JP, Koller WC, Cutler NR, Sramek JJ. Pramipexole in patients with early Parkinson's disease. Clin Neuropharm 1995; 18:338-347.
11. Adler CH, Singer C, O'Brien C, Hauser RA. Randomized placebo-controlled study of tolcopone in patients with fluctuating Parkinson's disease treated with levodopa-carbidopa. Arch Neurol 1998; 55:1089-1095.
12. Rascol O, Brooks DJ, Koczyn AD, De Deyn PP. A five year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. New Engl J Med 2000;342:1484-1491.
13. Shannon KM, Bennet JP, Friedman JH. The efficacy of pramipexole, a novel dopamine agonist, in mild to moderate Parkinson's disease. Neurology 1997;49:724-728.
14. Uitti RJ, Wharen RE, Turk MF, Lucas JA. Unilateral pallidotomy for Parkinson's disease. Neurology 1997;49:1072-1077.